Applegate W B
Department of Preventive Medicine, UTCHS College of Medicine, Memphis, TN 38105.
Postgrad Med. 1992 Jul;92(1):237-44. doi: 10.1080/00325481.1992.11701401.
Treatment of both systolic-diastolic and isolated systolic hypertension in patients over age 65 has been shown to decrease subsequent cardiovascular morbidity and mortality. In the European Working Party on High Blood Pressure in the Elderly study, the number of morbid and mortal cardiovascular events prevented in the treatment group was 29/1,000 person-years, whereas in the Systolic Hypertension in the Elderly Program, the number was 55/1,000 person-years. This magnitude of reduction is substantial, but in the case of primary prevention in the elderly, a large number of patients must be treated to benefit relatively few. Better strategies of targeting treatment based on risk over and above that of high blood pressure are needed. Certainly, patients with more than one cardiovascular risk factor or evidence of end-organ damage should be treated more aggressively.
65岁以上患者的收缩期-舒张期高血压和单纯收缩期高血压治疗已被证明可降低随后的心血管发病率和死亡率。在欧洲老年高血压工作组的研究中,治疗组预防的心血管病发病和死亡事件数量为每1000人年29例,而在老年收缩期高血压计划中,这一数字为每1000人年55例。这种降低幅度是相当大的,但就老年人的一级预防而言,必须治疗大量患者才能使相对较少的人受益。需要有比单纯高血压风险更优的基于风险的靶向治疗策略。当然,有一个以上心血管危险因素或存在靶器官损害证据的患者应接受更积极的治疗。